Status: Recruiting
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
This Phase 3 placebo-controlled study is planned to further investigate the efficacy, safety, and tolerability of apraglutide in the overall SBS-IF (short bowel syndrome associated with intestinal failure) population during 24 weeks of study treatment. It is expected that approximately 124 participants will be randomized worldwide to either apraglutide or placebo in a 1:1 ratio in this trial.
Participants needed: 124
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: VectivBio AGUpdated: Aug 4, 2026Locations: 94
Eligibility criteria
Participant must be ≥18 years of age, at the time of signing the informed consen... [+10]
Pregnancy and/or lactation and/or plans to become pregnant or to breastfeed. [+31]